NYSE:IBER

Ibere Pharmaceuticals (IBER) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IBER Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $10.18
▼
$10.18
50-Day Range: $10.15
▼
$10.21
52-Week Range: $9.74
▼
$10.75

Volume: 44,499 shs
Average Volume: 110,000 shs
Market Capitalization: $175.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Ibere Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Ibere Pharmaceuticals Stock (NYSE:IBER)

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

IBER Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive IBER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Holding & other investment offices
Sub-Industry: N/A
Current Symbol: NYSE:IBER
CUSIP: N/A
CIK: 1835205
Web: www.iberepharma.com
Phone: 267-765-3222
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.56 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -83.01%
Return on Assets: 4.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.09 per share
Price / Cash Flow: 112.42
Book Value: ($0.63) per share
Price / Book: -16.16

Miscellaneous

Outstanding Shares: 17,250,000
Free Float: 13,800,000
Market Cap: $175.61 million
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Osagie O. Imasogie Esq. (Age 61)
Chairman & CEO
Ms. Lisa M. Gray CPA (Age 58)
CPA, CVA, CFO, Exec. VP & Director
Mr. Zoltan Kerekes J.D. (Age 57)
COO, Exec. VP & Director

Key Competitors

View All Competitors

This page (NYSE:IBER) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ibere Pharmaceuticals (IBER) Stock Price, News & Analysis

About Ibere Pharmaceuticals Stock (NYSE:IBER)

IBER Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info